Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28674155 | 0.83 | JAK2 (0.44) | SMN1; SMN2NPC1RAB9ALMNANOTUM | |
| SCHEMBL21801345 | 0.79 | L3MBTL1 (0.36) | SMN1; SMN2LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL29456324 | 0.78 | PDE4B (0.42) | NPC1RAB9AMAPTPDE4BMAOB | |
| SCHEMBL2200166 | 0.74 | NPC1 (0.37) | SMN1; SMN2NPC1RAB9ALMNANOTUM | |
| SCHEMBL21178852 | 0.72 | SELE (0.33) | ALDH1A1 | |
| SCHEMBL23326620 | 0.71 | BAZ2B (0.40) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL29861199 | 0.71 | BAZ2B (0.40) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL23885609 | 0.69 | RAB9A (0.45) | TSHRSMN1; SMN2RAB9AMAPTRXFP1 | |
| SCHEMBL21801413 | 0.69 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL23108117 | 0.69 | CSNK1D (0.49) | TSHRSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3849986-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3740491-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200339589-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-10-29 | — | — | US | disclosed |
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019143977-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339589-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FGFR3 | ATM 946/4885TSHR 1407/4885SMN1; SMN2 444/4885 |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | ATM 683/4885TSHR 982/4885SMN1; SMN2 717/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | ATM 683/4885TSHR 982/4885SMN1; SMN2 717/4885 |
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | RET, ROR1, FGFR3 | ATM 946/4885TSHR 1407/4885SMN1; SMN2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.